# Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background

> **NCT02053727** · NA · WITHDRAWN · sponsor: **University of California, Los Angeles**

## Conditions studied

- Rheumatoid Arthritis
- Chronic Hepatitis B

## Interventions

- **DRUG:** Abatacept
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02053727
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-07
- **Primary completion:** 2018-06-12
- **Final completion:** 2018-06-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study team did not enroll any patients due to difficulty with recruitment.
- **Last updated:** 2020-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02053727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02053727, "Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02053727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*